non-radiographic axial spondyloarthritis (nr-axSpA)
If you’re still experiencing nr-axSpA symptoms after a TNF blocker like CIMZIA®*, RINVOQ is different and may help.
Learn how AbbVie could help you save. 1-800-2RINVOQ
If you’re still experiencing nr-axSpA symptoms after a TNF blocker like CIMZIA®*, RINVOQ is different and may help.
For adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation in whom a TNF blocker did not work well.
In a clinical study, RINVOQ helped:
Relieve nr-axSpA back pain and stiffness.
Reduce overall nr-axSpA disease activity, which was measured using a questionnaire about a range of symptoms including: back pain, joint pain and swelling, enthesitis (pain and swelling in areas like the heel and elbow), fatigue, and morning stiffness.
Improve physical function, making it easier to do everyday activities.
Select Important Safety Information
RINVOQ may cause serious side effects, including:
Learn more about these and other serious side effects >
See full Important Safety Information below.
QUESTION FOR YOU
What best describes the status of your nr-axSpA?
Pick one
Get the conversation going
Be prepared for your next rheumatologist visit.
You could pay as little as $0 a month
The RINVOQ Complete Savings Card may help eligible, commercially insured patients pay as little as $0 a month† for RINVOQ.
Hear how Stephanie takes on nr-axSpA with RINVOQ.
Start your RINVOQ story
Share your experience with RINVOQ to help inform and inspire others. To participate, please email us at info@SPEAKnetwork.net or call 877-861-6180.
Find a rheumatologist near you
Make sure you’re getting the most appropriate care for your condition. Partner with a doctor who specializes in diseases like nr-axSpA and ask if RINVOQ could help you.
*CIMZIA® (certolizumab pegol) is a registered trademark of UCB, Inc.
†Eligibility: Available to patients with commercial insurance coverage for RINVOQ® (upadacitinib) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit RINVOQSavingsCard.com or call 1.800.2RINVOQ for additional information. To learn about AbbVie’s privacy practices and your privacy choices, visit https://abbv.ie/corpprivacy.
RINVOQ is a prescription medicine used to treat adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation when a tumor necrosis factor (TNF) blocker medicine has been used, and did not work well or could not be tolerated. It is not known if RINVOQ is safe and effective in children with non-radiographic axial spondyloarthritis.
IMPORTANT SAFETY INFORMATION FOR RINVOQ/RINVOQ LQ (upadacitinib)
What is the most important information I should know about RINVOQ**?
RINVOQ may cause serious side effects, including:
Do not take RINVOQ if you are allergic to upadacitinib or any of the ingredients in RINVOQ. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.
What should I tell my HCP BEFORE starting RINVOQ?
Tell your HCP if you:
Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. RINVOQ and other medicines may affect each other, causing side effects.
Especially tell your HCP if you take:
If you are not sure if you are taking any of these medicines, ask your HCP or pharmacist.
What should I avoid while taking RINVOQ?
Avoid food or drink containing grapefruit during treatment with RINVOQ as it may increase the risk of side effects.
What should I do or tell my HCP AFTER starting RINVOQ?
What are other possible side effects of RINVOQ?
Common side effects include upper respiratory tract infections (common cold, sinus infections), shingles (herpes zoster), herpes simplex virus infections (including cold sores), bronchitis, nausea, cough, fever, acne, headache, increased blood levels of creatine phosphokinase, allergic reactions, inflammation of hair follicles, stomach-area (abdominal) pain, increased weight, flu, tiredness, lower number of certain types of white blood cells (neutropenia, lymphopenia, leukopenia), muscle pain, flu-like illness, rash, increased blood cholesterol levels, increased liver enzyme levels, pneumonia, low number of red blood cells (anemia), and infection of the stomach and intestine (gastroenteritis).
A separation or tear to the lining of the back part of the eye (retinal detachment) has happened in people with atopic dermatitis treated with RINVOQ. Call your HCP right away if you have any sudden changes in your vision during treatment with RINVOQ.
Some people taking RINVOQ may see medicine residue (a whole tablet or tablet pieces) in their stool. If this happens, call your HCP.
These are not all the possible side effects of RINVOQ.
How should I take RINVOQ/RINVOQ LQ?
RINVOQ is taken once a day with or without food. Do not split, crush, or chew the tablet. Take RINVOQ exactly as your HCP tells you to use it. RINVOQ is available in 15 mg, 30 mg, and 45 mg extended-release tablets. RINVOQ LQ is taken twice a day with or without food. RINVOQ LQ is available in a 1 mg/mL oral solution. RINVOQ LQ is not the same as RINVOQ tablets. Do not switch between RINVOQ LQ and RINVOQ tablets unless the change has been made by your HCP.
**Unless otherwise stated, "RINVOQ" in the IMPORTANT SAFETY INFORMATION refers to RINVOQ and RINVOQ LQ.
This is the most important information to know about RINVOQ. For more information, talk to your HCP.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
USES
RINVOQ is a prescription medicine used to treat:
It is not known if RINVOQ is safe and effective in children with ankylosing spondylitis, non-radiographic axial spondyloarthritis, ulcerative colitis, or Crohn's disease.
It is not known if RINVOQ is safe and effective in children under 12 years of age with atopic dermatitis.
It is not known if RINVOQ LQ is safe and effective in children with atopic dermatitis.
RINVOQ/RINVOQ LQ is a prescription medicine used to treat:
It is not known if RINVOQ/RINVOQ LQ is safe and effective in children under 2 years of age with polyarticular juvenile idiopathic arthritis or psoriatic arthritis.
If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/PatientAccessSupport to learn more.
US-RNQ-240084
Please see the Full Prescribing Information, including the Medication Guide, for RINVOQ.
Legal Notices. © 2024 AbbVie. All rights reserved. If you have any questions about AbbVie's RINVOQ.com website that have not been answered, click here. This website and the information contained herein is intended for use by US residents only, is provided for informational purposes only and is not intended to replace a discussion with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider and consider the unique characteristics of each patient.